Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for Glivec
The IPKat gets Spicy - more detail on the Indian Supreme Court Glivec Decision The IPKat gets Spicy - more detail on the Indian Supreme Court Glivec Decision Reviewed by Darren Smyth on Wednesday, May 15, 2013 Rating: 5
The IPKat in despair - What is to be done when senior courts don't understand novelty? The IPKat in despair - What is to be done when senior courts don't understand novelty? Reviewed by Darren Smyth on Thursday, May 09, 2013 Rating: 5
Public health and IP in India: Novartis loses Gleevec patent appeal at the Supreme Court Public health and IP in India: Novartis loses Gleevec patent appeal at the Supreme Court Reviewed by Stefano Barazza on Wednesday, April 03, 2013 Rating: 5
Novartis lose Indian Glivec/Gleevec appeal Novartis lose Indian Glivec/Gleevec appeal Reviewed by David Pearce on Monday, August 06, 2007 Rating: 5
Novartis fight for patentability in India Novartis fight for patentability in India Reviewed by David Pearce on Monday, January 29, 2007 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.